Key result
A hybrid therapy approach combining antiarrhythmic drugs, radiofrequency ablation, and implantable devices may improve treatment efficacy for atrial fibrillation on an individualized basis.
Why the study?
Does a hybrid therapy approach combining drugs, ablation, and devices improve treatment efficacy in patients with atrial fibrillation compared to monotherapy?
Does a hybrid therapy approach combining drugs, ablation, and devices improve treatment efficacy in patients with atrial fibrillation compared to monotherapy?
A hybrid approach combining antiarrhythmic drugs, radiofrequency ablation, and implantable devices may offer improved efficacy over monotherapy for the management of atrial fibrillation.
Atrial fibrillation (AF) is the most common sustained arrhythmia. Current therapies, including pharmacological treatment, radiofrequency ablation and implantable devices, showed significant limitation when used alone. Recently a number of combined therapies (hybrid therapy approach) were suggested. Radiofrequency ablation may improve the efficacy of drugs, pacing and automatic internal defibrillators. Antiarrhythmic drugs may play a similar role, enhancing preventive atrial pacing effectiveness as well as sinus rhythm restoration capabilities of cardioversion shocks and antitachycardia pacing. The availability of a wide range of therapeutic options suggests that the approach to the treatment of AF needs to be selected on an individual basis.
No takes yet. Share an insight, caveat, or question.
Alessandro Capucci (2001) conducted a review in Atrial fibrillation. Hybrid therapy (drugs, ablation, devices) was evaluated. A hybrid therapy approach combining antiarrhythmic drugs, radiofrequency ablation, and implantable devices may improve treatment efficacy for atrial fibrillation on an individualized basis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: